Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
According to average rates from the Zillow lender marketplace, mortgage rates are lower headed into the weekend.
The current 30-year fixed rate today, Saturday, September 19, 2026, fell by 1 basis point to 7.04%, the 20-year fixed rate fell 10 basis points to 6.82%, and the 5/1 ARM fell by 10 basis points to 7.04%.
Read more: Weekly survey of mortgage lenders with the lowest rates: Breaking the 7% barrier
Here are the current mortgage rates today, Saturday, September 19, 2026, according to the latest Zillow data:

#mortgage #fell #year

The ******* e Exploration Technologies (NASDAQ: SPCX) IPO was one of the most highly anticipated public offerings in years. Within a few days of going public, ******* eX had a valuation of $2.7 trillion after raising nearly $86 billion in funding.
Then things started going sideways. The stock began falling amid fears that ******* eX is spending too much on artificial intelligence (AI) infrastructure, and shares still trade below their opening price of $150 as of this writing. At one point, the share price fell enough to wipe out more than $1 trillion from ******* eX's valuation over a one-month span.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Another AI company, Anthropic, could go public as soon as next month. Like ******* eX, it's a highly anticipated IPO. But investors would be wise to take the recent ******* eX sell-off as a warning that buying IPO stocks when they first go public is rarely a good move. History shows it's far better to wait before buying -- here's why.
While there was an initial surge in interest for ******* eX, investors quickly turned their attention to the company's massive AI spending spree. The company's capital expenditures (capex) jumped 308% in the first six months of this year, compared to 2025, reaching $28.5 billion. That's a hefty sum, especially when you consider that ******* eX sales were just $12.5 billion over that same period.

#billion #first

Two former Robinhood engineers allegedly used confidential information about upcoming cryptocurrency listings to make profitable trades on decentralized exchange Hyperliquid, federal prosecutors said Tuesday.
Hefu Chai, 36, and Huaisong "Jerry" Xiang, 30, each face one count of commodities fraud and one count of wire fraud.
"Today's charges make clear that corporate insiders cannot evade the securities and commodities laws by trading based on misappropriated information in derivatives like perpetual futures, tokenized securities, or other similar financial instruments," U.S. Attorney Jamie McDonald said in a statement.
Perpetual futures, or "perps," let traders speculate on an **** et's price—often with leverage—without owning it. Unlike conventional futures, the derivatives do not expire. Hyperliquid is one of the largest decentralized platforms for trading perps and has faced increased regulatory scrutiny.
According to the DOJ, the engineers allegedly used nonpublic information about upcoming Robinhood Crypto token listings to buy related perpetual futures before the announcements, earning profits "for their own benefit" between 2025 and 2026. Each defendant earned more than $50,000 from the alleged scheme, the Justice Department said.

#futures #engineers

This year has already delivered one of the most extraordinary IPO periods in recent years. ****** eX (SPCX), Cerebras (CBRS), and Jersey Mike's (JMKE) have been some of the buzzier names to debut in public markets.
But this could be just the tip of the IPO iceberg as we look into the fall — and along with it, some very bold promises on future performance.
Anthropic (ANTH.PVT) has filed confidentially for a potential IPO as soon as October. The Claude creator may pitch to investors that its potential revenue opportunities are above $30 trillion, per a new report from the Wall Street Journal.
OpenAI (OPAI.PVT) is not far behind, judging by all the execs it has sent packing this summer. It too could follow Anthropic with a seemingly outlandish future revenue estimate.
"I actually like it [the revenue estimate] because it talks about sort of what the opportunity is. If it's enterprise, if it's consumer, it's coding, it's actually changing not only how we do work, but also how we develop products. I think it is viable," Connor Group managing partner Jim Neesen said on Yahoo Finance's Opening Bid. "I mean, if you look at their revenue growth, $65 billion is their run rate. They were $9 billion last year. That's a sevenfold increase. I do think that market opportunity is out there."

#revenue #estimate #Opportunity

Now that the **** e dust, er, the dust from the **** eX (SPCX) initial public offering (IPO) has settled, I decided to take another look at the IPO **** e at large. What did I find? Even in a strong period for stocks, like the past 52 weeks, IPOs are a **** shoot. That's based on the current holdings of the Renaissance IPO ETF (IPO), which have been public for at least 12 months.
With OpenAI and Anthropic thought of as the "next big thing" in IPO land, given their expected offerings, it should be noted that the last two headline-grabbing launches are not exactly posting stellar numbers out of the gate. Cerebras (CBRS) debuted in May of this year, and after hitting an intraday high of $386 just hours after its debut, it closed Wednesday at around $216.
Soros Fund Management Opened a New Position in Nebius During Q2. What This Means for NBIS Stock.
Ahead of Nvidia Earnings, Here's What Barchart Data Says Comes Next for NVDA Stock
Nvidia Earnings, Jackson Hole and Other Key Things to Watch this Week

#NVIDIA #spcx #even

Guinness Global Innovators, an investment management company, recently released its Q2 2026 quarterly investor update for its "Guinness Global Innovators Fund". You can download the letter here. The Guinness Global Innovators Fund focuses on investing in global companies that benefit from innovation in technology, communication, globalization, and management strategies. In the second quarter of 2026, the Guinness Global Innovators Fund returned 13.8% in GBP, compared with 13.0% for the MSCI World Index and 13.1% for the IA Global sector average. Easing Middle East tensions, falling oil prices, and renewed enthusiasm for artificial intelligence helped reverse much of the caution seen earlier in the year, with investors rotating back toward growth stocks and AI infrastructure beneficiaries. The Fund benefited from its overweight position in the Information Technology sector, while its overweight position in Communication Services detracted. Avoiding weaker Utilities, Materials, and Energy also supported relative performance. Also, please check the Fund's top five holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Guinness Global Innovators Fund highlighted Advanced Micro Devices, Inc. (NASDAQ:AMD) as a new holding. Advanced Micro Devices, Inc. (NASDAQ:AMD) is a leading semiconductor company that designs and manufactures AI accelerators, microprocessors, and graphics processing units. On August 21, 2026, Advanced Micro Devices, Inc. (NASDAQ:AMD) closed at $473.25 per share, reflecting a market capitalization of $772.57 billion. Advanced Micro Devices, Inc. (NASDAQ:AMD) posted a one-month return of -4.38%, while its shares gained 189.70% over the past 52 weeks.
Guinness Global Innovators Fund stated the following regarding Advanced Micro Devices, Inc. (NASDAQ:AMD) in its Q2 2026 investor letter:
"Advanced Micro Devices, Inc. (NASDAQ:AMD) is a fabless semiconductor company focused on high-performance and AI computing. It designs and sells a broad portfolio of AI-optimised processors and networking chips, positioning itself as a full-stack solutions provider across cloud and AI infrastructure while maintaining strong competitive positioning in PC and gaming endmarkets. AMD has notably closed the performance gap with Nvidia in recent years, driven by targeted acquisitions and sustained software investment. The Helios platform, built on AMD's acquisition of systems integrator ZT Systems, is AMD's first rack-scale system unifying graphical processing units (GPUs), computer processing units (CPUs) and Pensando networking into a frontier AI infrastructure solution, and should be a material growth driver from 2027 onwards. AMD is also structurally advantaged by a shift in data centre computational architecture. Its EPYC server CPUs offer industryleading performance-per-dollar and have taken substantial share from Intel in enterprise and cloud deployments. The rapid build-out of AI infrastructure is driving demand for high

The TJX Companies, Inc. (NYSE:TJX) had a solid second quarter on the surface, but the outlook raised some concerns. Sales increased 5.4% to $15.18 billion, just ahead of the $15.16 billion ***** ysts were expecting. Adjusted earnings came in at $1.22 per share, up 11% from a year earlier and above the $1.19 consensus.
The bigger issue was the third-quarter forecast. TJX expects adjusted earnings of $1.30 to $1.32 per share, excluding a six-cent benefit from tariff refunds. That is below the $1.35 ***** ysts were looking for and suggests the company is starting to feel some pressure from a more cautious consumer.
The slowdown at Marmaxx is probably the part investors are watching most closely. The division, which includes TJ Maxx and Marshalls, posted just 1% comparable-sales growth in the second quarter, down from 6% in the previous quarter. Since Marmaxx is TJX's largest division, a slowdown there matters.
Still, the company did not cut its outlook. TJX kept its comparable-sales growth target at 3% to 4% and raised its fiscal 2027 adjusted EPS forecast to $5.31-$5.36, up from $5.08-$5.15.
Photo by Carl Raw on Unsplash

#quarter #sales #adjusted #earnings

Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own targets even before Breathe Right and LaCorium Health joined the mix. But Clear Eyes, one of its historically strongest brands, is still working through a manufacturing bottleneck.
First quarter sales reached $265.7 million, up 6.5% from $249.5 million a year earlier, with organic growth of 3.2% once currency and the new Breathe Right contribution are excluded. Gains came from across the portfolio: Dramamine and Fleet lifted the GI category, Compound W led skin care higher, and TheraTears and Debrox both grew. Adjusted diluted EPS climbed to $0.98 from $0.95, and adjusted free cash flow hit a quarterly record of $83.7 million.
Then came the deals. Breathe Right closed June 12 and is expected to add about $200 million in annual revenue from a brand with over 90% consumer awareness sold in more than 20 countries, with a new Breathe Right Sport strip launching now alongside the Menthol variant introduced in 2025. Management said integration was largely complete within 60 days. LaCorium Health, closed July 1, adds roughly $40 million in annualized revenue and a leading dermal therapy brand in Australia's eczema and cold sore categories. Combined, the two deals are expected to add more than 20% to Prestige's annualized revenue base, and full-year guidance rose to $1.29 billion to $1.315 billion in sales and $4.55 to $4.65 in adjusted EPS.
Clear Eyes sales declined in the quarter as supply from the Pillar5 manufacturing facility stayed constrained, and management expects similar volatility in the second quarter before conditions stabilize in the back half of the year. International segment revenue fell 2.1% organically, which the company attributed to distributor order timing rather than weaker demand. Gross margin came in near 55%, down 120 basis points from a year earlier on higher transportation costs and product mix.
The acquisitions were funded with new debt. Prestige used a seven-year Term Loan B to pay for Breathe Right and LaCorium, then priced $400 million of new unsecured notes on July 15 to replace notes coming due. Net debt stood at approximately $2 billion as of June 30, and the company expects to end the fiscal year with leverage just below four times. Higher interest expense of roughly $100 million and additional amortization of about $33 million from the deals will weigh on results even as revenue grows. Order timing that helped the first quarter is expected to reverse into a modest organic revenue decline in the second quarter.

#million #year